SCHEMBL30186374

SCHEMBL30186374

C=C(C(=O)Nc1nc(-c2ccc(N3CCOCC3)nc2)cs1)c1ccc(O)c(O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 2/20 0.49
RRM2B Q7LG56 2/20 0.49
HDAC6 Q9UBN7 1/20 0.45
LMNA P02545 3/20 0.43
ERN1 O75460 1/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 2/20 0.43
RAF1 P04049 1/20 0.43
HPGD P15428 2/20 0.43
PHGDH O43175 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.41
HDAC10 Q969S8 1/20 0.41
MEN1 O00255 3/20 0.41
HSD17B10 Q99714 1/20 0.41
ATR Q13535 1/20 0.41
HTT P42858 1/20 0.41
KCNQ3 O43525 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186382 0.89 RRM1 (0.53) RRM1RRM2BLMNAMAPTSMN1; SMN2
SCHEMBL21505894 0.80 EGFR (0.43) LMNAERN1MAPTSMN1; SMN2MAPK1
SCHEMBL3311430 0.75 LMNA (0.60) LMNAMAPTSMN1; SMN2MAPK1RAF1
SCHEMBL21495029 0.74 MAPT (0.59) LMNAMAPTSMN1; SMN2MAPK1POLB
SCHEMBL28518770 0.74 LMNA (0.50) HDAC6LMNAMAPTSMN1; SMN2MAPK1
SCHEMBL30186397 0.71 RRM1 (0.50) RRM1RRM2BLMNAMAPTSMN1; SMN2
SCHEMBL7370511 0.70 ADK (0.57) LMNAMAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL11476003 0.69 LMNA (0.58) LMNAMAPTSMN1; SMN2MAPK1RAF1
SCHEMBL21495070 0.69 WNT3A (0.51) LMNAMAPTSMN1; SMN2MAPK1HPGD
SCHEMBL21484839 0.69 MAOA (0.51) LMNAMAPTSMN1; SMN2MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 RRM1 121/4885RRM2B 17/4885HDAC6 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.